Lunit to Present AI-Based Analysis Research at SITC 2026

Presents Research at SITC for Sixth Consecutive Year

Lunit said on October 14 that it will present two research abstracts using its artificial intelligence (AI) biomarker platform, Lunit SCOPE, at the 2026 Society for Immunotherapy of Cancer (SITC) Annual Meeting, which will be held in Phoenix, Arizona, from November 4 to 8.

At SITC, Lunit will present a study conducted jointly with Labcorp, a global diagnostics and clinical trial services company, titled "Comparing Histologic Immune Characteristics Between Homologous Recombination-Deficient (HRD) and Homologous Recombination-Proficient (HRP) Ovarian Cancer Through AI-Based Spatial Profiling."

Lunit will present two research abstracts using its artificial intelligence (AI) biomarker platform, Lunit SCOPE, at the 2026 Society for Immunotherapy of Cancer (SITC 2026), to be held in Phoenix, Arizona, from Nov. 4 to 8. Lunit

Lunit will also present a study conducted with global contract research organization (CRO) CellCarta, with which it jointly presented research findings at SITC last year. The study, titled "Identifying the Association Between Intratumoral Spatial Immune Architecture and Tumor-T-Cell Proximity and Response to Neoadjuvant Immunotherapy in Patients With Muscle-Invasive Bladder Cancer," will also be presented.

Lunit has presented research for six consecutive years since first showcasing its findings at SITC in 2021.

"Academic achievements are an important asset that can lead to business opportunities," said Lunit CEO Seo Beomseok. "We continue to lay the groundwork for the broad use of Lunit SCOPE in real-world healthcare settings."

This content was produced with the assistance of AI translation services.